Introduction {#sec1-1}
============

Orthodontic tooth movement has been defined as the production of a biological reaction to an interruption in the physiological equilibrium related to the dentofacial complex by an externally applied force \[[@ref1]\].

The lengthy duration of orthodontic treatment is considered a major disadvantage. This may lead to loss of patient compliance. This may be considered a problem especially for patients who require extraction of teeth as the treatment takes a relatively longer period than patients who don't require extraction of teeth \[[@ref2]\]. This may also lead to increasing the risk of caries \[[@ref3]\] and periodontal breakdown \[[@ref4]\]. Therefore, attention was paid to find methods to accelerate orthodontic tooth movement \[[@ref5]\]. These methods were surgical, mechanical or physical. Examples of these methods are low-level laser therapy, corticotomy, electrical current, pulsed electromagnetic fields, and dentoalveolar or periodontal distraction. Evidence showed that corticotomy is effective and safe to accelerate orthodontic tooth movement \[[@ref5]\]. Unluckily, very few patients can accept this surgical intervention to accelerate tooth movement due to its aggressive and invasive nature.

Another direction was focused on pharmacological approaches either locally or systemic administration to accelerate orthodontic tooth movement \[[@ref6]\], \[[@ref7]\].

Most of the previous systematic reviews concentrated on the physiological and surgical interventions with little concentration on the pharmacological interventions \[[@ref5]\], \[[@ref8]\], \[[@ref9]\], \[[@ref10]\].

This systematic review aims to investigate - in a systemic methodology and critical analysis - the available scientific literature discussing locally administrated pharmacological agents used in the acceleration of orthodontic tooth movement in humans.

Material and Methods {#sec1-2}
====================

This section was written following the PRISMA 2009 checklist \[[@ref11]\].

Protocol and Registration {#sec2-1}
-------------------------

There was neither a detailed protocol nor a systematic review registration done.

Information Sources and Search strategy {#sec2-2}
---------------------------------------

A search was conducted on electronic databases including PubMed, Lilacs, Web of Science (Thompson Reuters), EMBASE (OvidSP), and Cochrane Database of Systematic Reviews (Wiley) in addition to hand searching of relevant journals till June 2018. Only studies written in English were utilised.

The terms used in the search were shown in [Table 1](#T1){ref-type="table"}.

###### 

Terms used in the search strategy of the systematic review

  PICO item   Synonyms
  ----------- -----------------------------------------------------------------------------------------------------------------------------------
  P           Orthodontic patient OR Orthodontic therapy OR Orthodontic treatment Or Orthodox\* Or Tooth Movement (Mesh) OR teeth
  I           Pharmacological OR Drug Or Local Factor OR Pharmacol\* OR vitamin D OR Prostaglandin OR Cholecalciferol
  C           Control OR Regular Orthodontic treatment
  O           Accelerate tooth movement OR Fast treatment OR Treatment time OR Accelerate\* movement OR Rapid tooth movement OR Quick treatment

Eligibility Criteria {#sec2-3}
--------------------

The PICOS format (P = Population, I = Intervention, C = Comparison, O = Outcome, S = Study design) was constructed in order to state a clinical question with particular inclusion criteria.

**P** - Patients at any age undergoing orthodontic tooth movement

**I** - Local pharmacological interventions to accelerate tooth movement

**C** - Conventional orthodontic therapy without local pharmacological intervention.

**O** - Rate of tooth movement

**S** - Randomized controlled studies and non-randomized controlled studies

*Inclusion criteria:* - Local intervention; - Injectable; - Clinical trials; - Trial aiming to accelerate tooth movement.

*Exclusion Criteria:* - Animal study; - Systemic drug; - Histological study; - Trial comparing drugs decelerating tooth movement; - Subcutaneous, Intramuscular, Intravenous administration.

Review question {#sec2-4}
---------------

Are the local pharmacological interventions able to accelerate tooth movement compared to conventional orthodontic treatment without local pharmacological intervention?

Study selection {#sec2-5}
---------------

Two independent reviewers examined the article titles and abstracts. Full-text articles were retrieved when the articles were either potentially eligible or when the eligibility criteria couldn't be determined. Full-text articles were assessed following the inclusion and exclusion criteria. Reviewers' results were compared. Discussion of the data was done to resolve any disagreement.

Data Items {#sec2-6}
----------

From the studies that met our inclusion criteria, specific data items were extracted including (drug, frequency, dose, site, duration, total, dose, control, appliance, outcome, Risk Ratio, Mean Deference and side effects).

Data collection {#sec2-7}
---------------

The data items were extracted independently by 2 reviewers. The results were compared for accuracy and reassessment of the extracted data was done in case of any discrepancy until resolving the disagreement.

Bias Assessment {#sec2-8}
---------------

A quality assessment was performed based on the method described by Bondemark et al. \[[@ref12], [@ref13]\]. Following this method, studies were assigned to the grading of A, B, & C. A was considered high-quality evidence, B was a moderate value of evidence and C was considered the low value of evidence. In case of disagreement between the two reviewers or inadequately described criteria, the study was discussed thoroughly until reaching a consensus ([Table 2](#T2){ref-type="table"}).

###### 

Bondemark grading system

  Grade A                                                            Grade B                                                                             Grade C
  ------------------------------------------------------------------ ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------
  All criteria should be met:                                        All criteria should be met:                                                         One or more of the conditions below:
  A randomised clinical study or a prospective study                 Cohort study or retrospective case series with defined control or reference group   The high rate of attrition (1/3 or more of subjects lost during the study)
  Diagnostic reliability tests and reproducibility tests described                                                                                       
  Diagnostic reliability tests and reproducibility tests described   Poorly defined patient material                                                     
  Defined diagnosis and endpoints                                    Unclear diagnosis and endpoints                                                     
  Blinded outcome assessment                                         Defined diagnosis and endpoints                                                     

Summary measures and synthesis of the results {#sec2-9}
---------------------------------------------

The final level of evidence was determined based on Bondemark et al., \[[@ref12]\] The protocol divided evidence level to 1 (strong), 2 (moderate), 3 (limited) and 4 (inconclusive) ([Table 3](#T3){ref-type="table"}).

###### 

Evidence level

  Level   Evidence       Definition
  ------- -------------- --------------------------------------------------
  1       Strong         Minimum of 2 studies level A
  2       Moderate       At least 1 study level A and two studies level B
  3       Limited        Minimum of 2 studies level B
  4       Inconclusive   Less than 2 studies level B

Approach to Data synthesis {#sec2-10}
--------------------------

A meta-analysis was considered if the available collected data was adequate.

Results {#sec1-3}
=======

Study selection {#sec2-11}
---------------

A flowchart showed the selection process in each stage of the systematic review. ([Figure 1](#F1){ref-type="fig"}) Five hundred seventy-eight articles were excluded by title and abstract while 4 articles were selected for full review. Two of these articles weren't written in English \[[@ref14]\], \[[@ref15]\].

![Prisma flow chart](OAMJMS-7-882-g001){#F1}

Two articles were included in our review utilising relaxin \[[@ref16]\] and prostaglandin \[[@ref17]\] as local pharmacological interventions aiming to accelerate tooth movement.

Study characteristics {#sec2-12}
---------------------

*Methods*. One study was a randomised controlled study while the other study was a prospective study which was divided into 3 phases. Subjects. Total of 65 patients was involved in both studies. Intervention. Relaxin hormone and prostaglandin were used in selected studies.

Quality assessment {#sec2-13}
------------------

One study was graded A (High value of evidence) \[[@ref16]\], while the other was graded B (moderate level of evidence) \[[@ref17]\].

Results of Individual Studies {#sec2-14}
-----------------------------

The primary outcome assessed in both studies was the effect of the local agent in the acceleration of orthodontic tooth movement. Secondary outcome included side effects resulted from using prostaglandin and effect of Relaxin on relapse ([Table 4](#T4){ref-type="table"}). The effect of prostaglandin was investigated both macroscopically and using radiographic images. There was no side effect observed on the gingiva or bones. Relaxin showed no effect on short-term stability.

###### 

Results of individual data

  Title                                                                                                                                    Author                                                                                              Year   Design of the study   Number   Groups   Split-mouth
  ---------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------ --------------------- -------- -------- -------------
  A randomized, placebo-controlled clinical trial on the effects of recombinant human relaxin on tooth movement and short-term stability   Susan P. McGorray, a Calogero Dolce, b Susan Kramer, c Dennis Stewart, d and Timothys T. Wheelere   2012   RCT                   40       2        no
  Clinical application of prostaglandin E1 (PGE1) upon orthodontic tooth movement.                                                         Yamasaki, K Shibata, Y.Imai, STani, Y.Shibasaki, Y Fukuhara, T                                      1984   3 phases              25       3        yes

  Title                                                                                                                                    Drug                            Sample         Frequency                                               Dose               Site                                                                        Duration        Total dose                                              Control          Appliance and force
  ---------------------------------------------------------------------------------------------------------------------------------------- --------------- --------------- -------------- ------------------------------------------------------- ------------------ --------------------------------------------------------------------------- --------------- ------------------------------------------------------- ---------------- ------------------------------------------------
  A randomized, placebo-controlled clinical trial on the effects of recombinant human relaxin on tooth movement and short-term stability   Human relaxin                   40             /7 days                                                 25µg/site/0.1 ml   2 sites buccal and lingual of the target teeth                              56              400µg                                                   Vehicle 1.6 ml   Invisalign vacuum aligners
  Clinical application of prostaglandin E~1~ (PGE~1~) upon orthodontic tooth movement.                                                     PGE~1~          Phase I         9              3 to 5 times                                            10 µg PGE~1~       Injection of the submucosal area of the buccal side of the first premolar   Up to 26 days                                                           Lidocaine        Double spring soldered on lingual arch(100 gm)
  Phase II                                                                                                                                 8               3 to 4 times    10 µg PGE~1~   Injection of the submucosal area distal to the canine   Up to 21 days                                                                                  Lidocaine       Sectional contraction loop (150 gm)                                      
  Phase III                                                                                                                                8               5 to 13 times   10 µg PGE~1~   Injection of the submucosal area distal to the canine   Up to 5 months                                                                                 Lidocaine       Compressed open- coil springs or ringlets (150 grams)                    

  Title                                                                                                                                    Outcome                                            Frequency days            Duration (days)   Dose               Mean difference (intervention/control) (ratio)   Side effects
  ---------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- ------------------------- ----------------- ------------------ ------------------------------------------------ --------------
  A randomized, placebo-controlled clinical trial on the effects of recombinant human relaxin on tooth movement and short-term stability   Rate of tooth movement, rate of relapse            /7                        56                25µg/site/0.1 ml   1                                                No
  Clinical application of prostaglandin e~1~ (pge~1~) upon orthodontic tooth movement.                                                     Otm and side effect was examined macroscopically   3 to 5 times in 26 days   15-28             10 µg pge~1~       2.14±0.33                                        No
  3 to 4 times in 14 days                                                                                                                  10-21                                              Not mentioned                                                                                                   
  5 to 13 times                                                                                                                            45-144                                             1.6 ±0.09                                                                                                       

Risk of bias {#sec2-15}
------------

The study investigating Prostaglandin effect was found to be of high risk of bias as it was not a randomised controlled trial, while some concerns regarding the allocation concealment were detected in the other study investigating Relaxin effect.

Synthesis of Data {#sec2-16}
-----------------

A meta-analysis was not possible due to the presence of insufficient studies.

Discussion {#sec1-4}
==========

This study aimed to investigate the ability of the local pharmacological agent to accelerate orthodontic tooth movement. Surgical interventions have shown potential in the acceleration of orthodontic movement \[[@ref8]\]. Its side effects had always been a barrier in the generalisation of these interventions. Local pharmacological interventions would be an excellent replacement if proven their efficiency, especially if not accompanied by any side effects. In spite of the huge focus on the acceleration of orthodontic tooth movement, there were only 2 human studies investigating the effect of local pharmacological agents on the acceleration of OTM. There were much more animal studies \[[@ref18]\], \[[@ref19]\], \[[@ref20]\], \[[@ref21]\] on the same topic. The obvious reason was the risk of side effects that accompany the tested interventions \[[@ref22]\].

From the current systematic review, Relaxin \[[@ref16]\] and Prostaglandin \[[@ref17]\] were tested on humans. Prostaglandin showed a marked increase in OTM. The study was divided into 3 phases in which all phases showed acceleration of OTM in intervention sides, yet the study was considered having a high risk of bias. The study wasn't a randomised controlled study, and the sample size wasn't enough for each phase.

Evidence level was below moderate regarding Relaxin and inconclusive regarding prostaglandin according to Bondemark grading system \[[@ref12]\]. Only 1 study was found which was graded A for Relaxin. While for Prostaglandin, only one study which was graded B was found.

The RCT investigating Relaxin showed that there was no significant difference and was considered of low risk of bias. Yet they used aligners which might not have delivered a consistent force-that couldn't be measured-necessary for proper comparison. Both studies were based on submucosal injection in the areas adjacent to OTM.

This study showed the need for further studies investigating the use of local pharmacological agents in the acceleration of orthodontic tooth movement.

Strength and limitations {#sec2-17}
------------------------

Previous studies investigated different approaches with no concentration on the pharmacological approaches \[[@ref23]\]. This study, however, focused on the local pharmacological agents used in orthodontic treatment to accelerate tooth movement. There were not enough studies to conduct a meta-analysis. There were only a few heterogynous human studies. The quality of evidence was poor in that topic indicating the need for further studies to reach a proper conclusion.

Conclusion {#sec1-5}
==========

There is below moderate evidence showing no effect of relaxin on orthodontic tooth movement, while inconclusive evidence was found regarding Prostaglandin in the acceleration of orthodontic tooth movement. More prospective well-conducted clinical trials are needed to reach a proper conclusion regarding the local pharmacological agents which can be safely used to accelerate orthodontic tooth movement.

**Funding:** This research did not receive any financial support

**Competing Interests:** The authors have declared that no competing interests exist
